Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma L Turner

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialJ Athene Lane, Jenny L Donovan, Michael Davis, et al.
BMC Medical Research Methodology|January 24, 2015
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)Naomi J Williams, Elizabeth M Hill, Siaw Yein Ng, et al.
Journal of Clinical Epidemiology|June 7, 2019
Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort studyJenny L Donovan, Brent Opmeer, Grace J Young, et al.
BMJ Open|November 1, 2017
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort studyGrace J Young, Sean Harrison, Emma L Turner, et al.
Journal of Clinical Epidemiology|December 31, 2017
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trialJenny L Donovan, Grace J Young, Eleanor I Walsh, et al.
Journal of Medicinal Chemistry|April 24, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of GlioblastomaMichael J Rawling, Arpita Ray-Sinha, Michael Bestwick, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
JAMA|April 6, 2024
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialRichard M Martin, Emma L Turner, Grace J Young, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialJ Athene Lane, Jenny L Donovan, Michael Davis, et al.
BMC Medical Research Methodology|January 24, 2015
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)Naomi J Williams, Elizabeth M Hill, Siaw Yein Ng, et al.
Journal of Clinical Epidemiology|June 7, 2019
Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort studyJenny L Donovan, Brent Opmeer, Grace J Young, et al.
BMJ Open|November 1, 2017
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort studyGrace J Young, Sean Harrison, Emma L Turner, et al.
Journal of Clinical Epidemiology|December 31, 2017
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trialJenny L Donovan, Grace J Young, Eleanor I Walsh, et al.
Journal of Medicinal Chemistry|April 24, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of GlioblastomaMichael J Rawling, Arpita Ray-Sinha, Michael Bestwick, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
JAMA|April 6, 2024
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialRichard M Martin, Emma L Turner, Grace J Young, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
Pageof 5